Pfizer Inc. news

   Watch this stock
Showing stories 1 - 10 of about 172   

Articles published

PFE 31.99 +0.05 (0.16%)
price chart
3 Pharma Giants Growing Significantly Faster Than Pfizer, Inc.
The largest pharmaceutical company in the world, Pfizer (NYSE: PFE ) , is a fixture in a number of retirement portfolios, and it's a staple holding of income investors looking for exposure to the healthcare sector.
Pfizer, Inc. Invests in Growth... Literally
Pfizer Inc. (NYSE: PFE ) locked up commercial rights to Opko Health's (NYSE: OPK ) long-lasting human growth hormone in a deal worth hundreds of millions of dollars.
Pfizer, OPKO Health Partner on Growth-Hormone Treatment  Wall Street Journal
Opko, Pfizer sign pact to develop & commercialise long-acting hGH-CTP
Related articles »  
3 Reasons Pfizer, Inc. Could Soar in 2015
Considering what a strong year it's been for health care stocks, especially biotech and pharmaceutical companies, Pfizer's (NYSE: PFE ) 7% year-to-date gains might leave a lot to be desired among shareholders. Pfizer struggled in 2014, as it has in ...
Related articles »  
New Pfizer bid unlikely says AstraZeneca CEO
"I consider it unlikely that Pfizer (NYSE:PFE) will return with a bid," reports Swedish business daily Dagens Industri quoting AstraZeneca (NYSE:AZN) CEO Pascal Soriot.
Pfizer Unlikely To Make New Bid For AstraZeneca: Swedish Newspaper  Macro Insider
Related articles »  
Pfizer exec leaving to run Bucks County CRO
A Pfizer Inc. executive is leaving the pharmaceutical giant to take over as president and CEO of BioClinica Inc., a Bucks County clinical trial services company.
Pfizer exec to head BioClinica
BioClinica Names Dr. John Hubbard Chief Executive Officer  MarketWatch
Related articles »  
iTeos Therapeutics Announces License and Collaboration with Pfizer Inc. for ...
GOSSELIES, Belgium, Dec. 8, 2014 /PRNewswire/ -- iTeos Therapeutics SA announced today a strategic collaboration with Pfizer Inc. pursuant to which iTeos will license to Pfizer rights to iTeos' pre-clinical compounds targeting Indoleamine 2,3 ...
Latest Top News Stories: Avanir Pharmaceuticals Inc (NASDAQ:AVNR), Pfizer ...  Markets Emerging
Related articles »  
5 Things Pfizer, Inc.'s Management Wants You to Know
Pharmaceutical behemoth Pfizer (NYSE: PFE ) delivered its third-quarter earnings report late last month and all things considered it was pretty much in-line with Wall Street's expectations.
Bristol-Myers Squibb and Pfizer Inc.'s Bet on This Small Biotech Stock Could ...
Last week, Portola Pharmaceuticals (NASDAQ: PTLA ) reported interim results from a phase 3 trial of its drug andexanet alfa at the American Heart Association's Scientific Sessions 2014 conference -- results that could have big implications on Bristol ...
Related articles »  
Pfizer Inc. (NYSE:PEE) (PFE) Results from Phase III of Nerve-Pain Drug are ...
Pfizer Inc. (NYSE:PFE) posted positive results from the study of Phase III evaluating pregabalin controlled-release (CR) treatment, known as Lyrica, treatment for postherpetic neuralgia, or nerve damage pain.
Pfizer Inc. (NYSE:PFE) Enrollment Of The First Patient In A Multicenter ...  StreetWise Report
Pfizer Price Target Raised to $35.00 (PFE)  WKRB News
Related articles »  
Pfizer Is A Great Income Stock On A Pullback (PFE)
Shareholders of pharma giant Pfizer (NYSE:PFE) have made a lot of money in the past few years. The company, which has generally been regarded as a yield play, has seen the value of its shares rise steadily since the stock consolidated under $20 three ...